Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
LONDON - Ananda Pharma plc (AQSE:ANA, OTC: ANANF) announced Tuesday that shareholders approved all resolutions at its Annual General Meeting held earlier in the day.
The UK-based biopharmaceutical company, which develops cannabidiol medicines for complex chronic conditions, reported that proxy votes received ahead of the meeting showed overwhelming support for all proposals, with approval rates exceeding 99.9% across the board.
Shareholders voted to approve the company’s financial statements and re-elect all board members, including Charles Morgan, Jeremy Sturgess-Smith, Stuart Piccaver, Clive Page, Melissa Sturgess, and John Treacy. The resolution to reappoint auditors also passed with 99.997% approval.
Additionally, resolutions regarding the allotment of securities and pre-emption rights received strong support, with the latter garnering 99.963% approval with 84 votes withheld.
Ananda Pharma focuses on developing regulatory approved cannabidiol medicines for conditions including epilepsy, endometriosis, and chemotherapy pain. The company’s epilepsy trials are funded by NHS England and NIHR, while its endometriosis research receives funding from NHS Scotland and its chemotherapy pain studies are supported by NIHR.
The information was disclosed in a regulatory announcement based on a company press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.